In the latest issue of The Cancer Letter, NBCC’s Chief Policy Officer Melanie Wyne and other experts discuss the history and successes of the Department of Defense Congressionally Directed Research Program, including the Department of Defense Breast Cancer Research Program (DOD BCRP)– and what significant cuts could mean for future treatments, scientific discoveries, and patients.
Wyne on the impact of the DOD BCRP:
The DOD program was developed in order to be very innovative… From our perspective, we feel like the breakthrough treatment that’s going to ultimately end breast cancer—it’s most likely to come out of the DOD program.
